Review of antifungal therapy and the severity index for assessing onychomycosis: Part I

References

• Marty J. P. L. Amorolfine nail lacquer: A novel formulation. J Eur Acad Dermatol Venereol 1995; 4(Suppl 1)S17–S22
   Google Scholar
• Gupta A. K., Fleckman P., Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43: S70–S80
   PubMed Web of Science ®Google Scholar
• Effendy I. Therapeutic strategies in onychomycosis. J Eur Acad Dermatol Venereol 1995; 4(Suppl 1)S3–S10
   Google Scholar
• Gupta A. K., Joseph W. S. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of toenails in the United States. J Am Podiatr Med Assoc 2000; 90: 495–501
   PubMed Web of Science ®Google Scholar
• Seebacher C., Ulbricht H., Wörz K. Results of a multicentre study with ciclopirox nail lacquer in patients with onychomycosis. Hautnah Myk 1993; 3: 80–4
   Google Scholar
• Nolting S., Ulbricht H. Untersuchungen zur Applikationsfrequenz von Ciclopirox‐lack (8%) bei der Behandlung von Onychomycosen. Jatrox Derma 1997; 11: 20–6
   Google Scholar
• Polak A., Jäckel A., Noack A., Kappe R. Agar sublimation test for the in vitro determination of the antifungal activity of morpholine derivatives. Mycoses 2004; 47: 184–92
   PubMedGoogle Scholar
• Flagothier C., Piérard‐Franchimont C., Piérard G. E. New insights into the effect of amorolfine nail lacquer. Mycoses 2005; 48: 91–4
   PubMed Web of Science ®Google Scholar
• Rigopoulos D., Katsambas A., Antoniou C., Christofidou E., Balaskas E., Stratigos J. Discoloration of the nail plate due to the misuse of amorolfine 5% nail lacquer. Acta Derm Venereol 1996; 76: 83–4
   PubMedGoogle Scholar
• Kim B. J., Ro B. I. Hyperpigmentation due to the overuse of amorolfine nail lacquer. Korean J Med Mycol 2002; 7: 224–6
   Google Scholar
• Lee J. H., Roh K. Y., Park H. J., Lee J. Y., Cho B. K. Painful nail due to the use of amorolfine nail lacquer. Third Korea–China International Conference of Dermatology and Mycology, SeoulKorea, May 31 to June 1, 2001, Poster 51
   Google Scholar
• Baran R., de Donker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol 1996; 76: 82–3
   PubMed Web of Science ®Google Scholar
• Hay R. J. Chronic dermatophyte infections. Superficial fungal infections, J Verbov. MTP Press, LancasterUK 1986; 23–4
   Google Scholar
• Roberts D. T., Evans E. G. V. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998; 138: 189–90
   PubMed Web of Science ®Google Scholar
• Baran R., Tosti A., Piraccini B. M. Uncommon clinical patterns of Fusarium nail infection: Report of three cases. Br J Dermatol 1997; 136: 424–7
   PubMedGoogle Scholar
• Rollman O., Johansson S. Hendersonula toruloidea infection: Successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine. Acta Derm Venereol 1987; 67: 506–10
   PubMedGoogle Scholar
• Dominguez‐Cherit J., Teixeira F., Arenas R. Combined surgical and systemic treatment of onychomycosis. Br J Dermatol 1999; 140: 778–80
   PubMedGoogle Scholar
• Baran R., Hay R. J. Partial surgical avulsion of the nail in onychomycosis. Clin Exp Dermatol 1985; 10: 413–18
   PubMed Web of Science ®Google Scholar
• Baran R., Bureau H. Surgical treatment of recalcitrant chronic paronychia of the fingers. J Dermatol Surg Oncol 1981; 7: 106–7
   PubMedGoogle Scholar
• South D. A., Farber E. M. Urea ointment in non surgical avulsion of nail dystrophies. Reappraisal. Cutis 1980; 26: 609–12
   Google Scholar
• Buselmeier T. Combination urea and salicylic acid ointment nail avulsion in non dystrophic nails: Follow‐up observation. Cutis 1980; 25: 397–405
   PubMedGoogle Scholar
• Dorn M., Kienitz T., Ryckmanns F. Onychomycosis: Experience with non traumatic nail avulsion. Hautarzt 1980; 31: 30–4
   PubMedGoogle Scholar
• Torres‐Rodriguez J. M., Madreny N., Nicolas M. C. Non‐traumatic topical treatment of onychomycosis with urea associated with bifonazole urea in the two‐phase treatment of onychomycosis. Mycoses 1991; 34: 499–504
   PubMed Web of Science ®Google Scholar
• Bonifaz A., Guzman A., Garcia C., Sosa J., Saul A. Efficacy and safety of bifonazole urea in the two‐phase treatment of onychomycosis. Int J Dermatol 1995; 34: 500–3
   PubMed Web of Science ®Google Scholar
• Baran R., Coquard F. Combination of fluconazole and urea in a nail lacquer for treating onychomycosis. J Dermatolog Treat 2005; 16: 52–5
   PubMed Web of Science ®Google Scholar
• Di Chiacchio N., Kadunc B. V., De Almeida A. R. T., Madeira C. L. Nail abrasion. J Cosmet Dermatol 2003; 2: 150–2
   PubMedGoogle Scholar
• Haneke E. The potential risks of not treating onychomycosis. Proceedings of the 2nd International Symposium on Onychomycosis, Florence, 1995. Gardiner‐Caldwell Comm Ltd, MacclesfieldUK 1966; 12–14
   Google Scholar
• Grant S. M., Clissold S. P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310–44
   PubMed Web of Science ®Google Scholar
• Haria M., Bryson H. M., Goa K. L. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996; 51: 585–620
   PubMed Web of Science ®Google Scholar
• De Doncker P., Decroix J., Piérard G. E., Roelant D., Woestenborghs R., Jacqmin P., et al. Antifungal pulse therapy in onychomycosis: A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1‐week pulse with itraconazole. Arch Dermatol 1996; 132: 34–41
   PubMed Web of Science ®Google Scholar
• Nolting S. Satellite Symposium. Onychomycosis. New approaches in therapy., Proceedings of the 19th World Congress of Dermatology, Sydney, Australia, June 18 1997
   Google Scholar
• Fischbein A., Haneke E., Lacner K., et al. Comparative evaluation of oral fluconazole and oral ketoconazole in the treatment of fungal infections of the skin. Int J Dermatol 1992; 31(Suppl 2)12–16
   Google Scholar
• Rex J. H., Rinaldi M. G., Pfaller M. A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1–8
   PubMed Web of Science ®Google Scholar
• Goa K. L., Barradell L. B. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658–90
   PubMed Web of Science ®Google Scholar
• Rich P., Scher R. K., Breneman D., Savin R. C., Feingold D. S., Konnikov N., et al. Pharmacokinetics of three doses of once‐weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38: S103–9
   PubMed Web of Science ®Google Scholar
• Savin R. C., Drake L., Babel D., Stewart D. M., Rich P., Ling M. R., et al. Pharmacokinetics of three once‐weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 1998; 38: S110–16
   PubMedGoogle Scholar
• Scher R. K., Breneman D., Rich P., Savin R. C., Feingold D. S., Konnikov N., et al. Pharmacokinetics and efficacy of once‐weekly fluconazole (150, 300 or 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38: S77–86
   PubMedGoogle Scholar
• Drake L., Babel D., Stewart D., Rich P., Ling M. R., Breneman D., et al. Once‐weekly fluconazole (150, 300 or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 1998; 38: S87–S94
   PubMedGoogle Scholar
• Ling M. R., Swinyer L. J., Jarratt M. T., Falo L., Monroe E. W., Tharp M., et al. Once‐weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38: S95–S102
   PubMed Web of Science ®Google Scholar
• Fräki J. E., Heikkila H. T., Kero M. O., Kuokkanen K. E., Oksman R. O., Rantanen T. T., et al. An open‐label, noncomparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis. Curr Therap Res 1997; 58: 481–91
   Google Scholar
• Ryder N. S. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126: 2–7
   PubMed Web of Science ®Google Scholar
• Balfour J. A., Faulds D. Terbinafine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259–84
   PubMed Web of Science ®Google Scholar
• Faergemann J., Zehender H., Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis‐epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121–6
   PubMed Web of Science ®Google Scholar
• Hall M., Monka C., Krupp P., O'Sullivan D. Safety of oral terbinafine: Results of a post‐marketing surveillance study in 25.884 patients. Arch Dermatol 1997; 133: 1213–19
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez L. A., Duque A., Castellsague J., Perez‐Gutthann S., Stricker B. H. A cohort study of the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999; 48: 847–52
   PubMed Web of Science ®Google Scholar
• Stricker B. H., van Riemsdijk M. M., Sturkenboom M. C., Ottervanger J. P. Taste loss to terbinafine: A case–control study of potential risk factors. Br J Clin Pharmacol 1996; 42: 313–18
   PubMed Web of Science ®Google Scholar
• Vantaux P., Grasset D., Nougue J., Lagier E., Seigneuric C. Hépatite aiguë en rapport avec la prise de terbinafine. Gastroenterol Clin Biol 1996; 20: 402–3
   PubMedGoogle Scholar
• Rzany B., Mockenhaupt M., Gehring W., Schöpf E. Stevens–Johnson syndrome after terbinafine therapy. J Am Acad Dermatol 1994; 30: 509
   PubMedGoogle Scholar
• Carstens J., Wendelboe P., Sogaard H., Thestrup‐Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Dermatol Venereol 1994; 74: 391–2
   PubMed Web of Science ®Google Scholar
• Jenssen J. C. Pharmacokinetics of lamisil in humans. J Dermatol Treat 1990; Suppl 2: 15–18
   Google Scholar
• Svejgaard E. L., Brandrup F., Kragballe K., Larsen P. O., Veien N. K., Holst M., et al. Oral terbinafine in toenail dermatophytosis. A double‐blind, placebo‐controlled multi‐center study with 12 months' follow‐up. Acta Dermatol Venereol 1997; 77: 66–9
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B., Olafsson J. H., Steinsson J. B., Paul C., Billstein S., Evans E. G. Long‐term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: A 5‐year blinded prospective follow‐up study. Arch Dermatol 2002; 138: 353–7
   PubMed Web of Science ®Google Scholar
• Cribier B. J., Bakshi R. Terbinafine in the treatment of onychomycosis: A review of its efficacy in high‐risk populations in patients with nondermatophyte infections. Br J Dermatol 2004; 150: 414–20
   PubMed Web of Science ®Google Scholar
• Segal R., Kritzman A., Cividalli L., Samra Z., David M., Tiqva P. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35: 958–61
   PubMed Web of Science ®Google Scholar
• Nolting S., Brautigam M., Weidinger G. Terbinafine in onychomycosis with involvement by non‐dermatophytic fungi. Br J Dermatol 1994; 130(Suppl 43)16–21
   PubMedGoogle Scholar
• Zaidi Z., Jafri N., Khan K., Hasan P., Kapadia N. Open label trial of the efficacy and tolerability of Lamisil (terbinafine) 500 mg once daily in the treatment of onychomycosis due to candida. J Pak Med Assoc 1996; 46: 258–60
   PubMedGoogle Scholar
• Goodfield M. J. D., Evans E. G. V. Combined treatment with surgery and short duration oral antifungal therapy in patients with limited dermatophyte toenail infection. J Dermatolog Treat 2000; 11: 259–62
   Web of Science ®Google Scholar
• Goodfield M. J. D., Bosanquet N., Evans E. G. V., Winther‐Pedersen A. L., Perrin V. L. Cost effective clinical management of onychomycosis. Br J Med Econ 1994; 7: 15–23
   Google Scholar
• Baran R., Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosisi: An overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005; 19: 21–9
   PubMed Web of Science ®Google Scholar
• Pierard G. E., Pierard‐Franchimont C., Arrese J. E. The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology 2000; 200: 185–7
   PubMed Web of Science ®Google Scholar
• Goffin V., Arrese J. E., Pierard G. E. Onychomycoses récalcitrantes et le ‘low‐coast BOAT’ au fluconazole. Skin 2002; 5: 145–7
   Google Scholar
• Pierard G. E., Pierard‐Franchimont C., Arrese J. E. The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol 2000; 38: 391–2
   PubMed Web of Science ®Google Scholar
• Gupta A. K., Leonardi C., Stoltz R. R., Pierce P. F., Conetta B. Ravuconazole onychomycosis group. A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005; 19: 437–43
   PubMed Web of Science ®Google Scholar
• Mamta P., Sushil S. Utilization of pericarp of Citrus sinensis oil for the development of natural antifungal against nail infection. Curr Sci 2003; 84: 1512–15
   Google Scholar
• Gayoso C. W., Lima E. O., Oliveira V. T., Pereira F. O., Souza E. L., Lima I. O., et al. Sensitivity of fungi isolated from onychomycosis to Eugenia cariophyllata essential oil and eugenol. Fitoterapia 2005; 76: 247–9
   PubMed Web of Science ®Google Scholar
• Baran R., Coquard F. Combination of fluconazole and urea in a nail lacquer for treating onychomycosis. J Dermatolog. Treat 2005; 16: 52–5
   PubMed Web of Science ®Google Scholar
• Kamp H., Tietz H. J., Lutz M., Piazena H., Sowyrda P., Lademann J., et al. Antifungal effects of 5‐aminolevulinic acid PDT in Trichophyton rubrum. Mycoses 2005; 48: 101–7
   PubMed Web of Science ®Google Scholar
• Gupta A. K. Photodynamic therapy for onychomycosis of fingernails. AAD 61st Meeting, San Francisco, 2003; 440
   Google Scholar
• Donnely R. F., Carron P. A., Lightowler J. M., Woolfson A. D. Bioadhesive patch‐based delivery of 5‐aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J Control Release 2005; 103: 381–92
   PubMedGoogle Scholar